Hocqueloux L, Gubavu C, Prazuck T, et al. - Genital sub-studies were pooled from 2 clinical trials in this area. Individuals were assigned randomly in 1:1 ratio to continue abacavir/lamivudine/dolutegravir or switch to dolutegravir (MONCAY trial), or to continue tenofovir/emtricitabine + a third agent or switch to tenofovir/emtricitabine (TRULIGHT trial). Via ultrasensitive polymerase chain reaction, HIV-RNA and HIV-DNA were amplified. This study enrolled a total of 64 participants (35 males, 29 females). No evidence of increased HIV-RNA and/or -DNA shedding was found in the genital fluids of people who maintained undetectable plasma HIV-RNA during lower drug regimens. .